Phase 2 N=89 Conversion to Envarsus Post Kidney Transplant Protects Against BK Infection
Renal Transplant Infection
Primary: Participants Will Experience Less BK Infection Episodes Based on Viruria Results.
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=92 Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change in Glycated Haemoglobin (HbA1c): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide) — -2.2; -1.9; -2.2; -2.0 Percentage…
Phase 2 N=76 A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12 — -1.83; -2.06 scores on a scale
Phase 2 N=40 Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome
Prader-Willi Syndrome
Primary: Number of Participants Who Experienced a Treatment-Emergent Adverse Event (TEAE) - Period 2 — 4; 11; 6; 11 Participants
Phase 2 N=51 The Role of 68Ga-PSMA-11 PET (Prostate Specific Membrane Antigen) in Surgery Guidance in Prostate Cancer
Prostate Cancer
Primary: Sensitivity of PSMA-PET and MRI Imaging Preoperatively for Predicting Extra-prostatic Extension — 86; 57 percentage — p=<0.05
Phase 2 N=50 A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)
Lymphoma, Large B-Cell, Diffuse
Primary: Subcutaneous Serum Rituximab Trough Concentration (Ctrough SC) and Intravenous Serum Rituximab Trough Concentration (Ctrough IV) — 90.7; 137.4 micrograms/milliliter…
Phase 2 N=87 Trial to Investigate the Effect of ESN364 in Early Postmenopausal Women Suffering From Hot Flashes
Hot Flashes
Primary: Change From Baseline to Week 12 in The Weekly General Hot Flash Score — -12.19; -26.51 score on a scale — p=<0.001
Phase 2 N=17 Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck
Head and Neck Squamous Cell Carcinoma
Primary: Locoregional Control — 17 participants
Phase 2 N=15 Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)
Anaemia
Primary: Percentage of Fractional Oral Iron Absorption Following Treatment With Daprodustat and rhEPO — 20.64; 20.62 Percentage (%) of iron absorbed — p=0.9971
Phase 2 N=37 Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib
Lung Adenocarcinoma · Lung Neoplasms
Primary: Progression Free Survival 1 (PFS 1) for ALL Participants Who Started Osimertinib on Trial Until First Progression of Disease or Clinical Progression, or Death Any Cause…
Phase 2 N=28 Mild Encephalopathy in the Newborn Treated With Darbepoetin
Neonatal Encephalopathy · Hypoxic-Ischemic Encephalopathy Mild
Primary: Normal Neurodevelopment — 13; 14 Participants
Phase 2 N=142 Impact of Colchicine and Low-dose Naltrexone on COVID-19
Covid19
Primary: In Patients Hospitalized With Moderate COVID-19, the Impact of Colchicine and LDN, Alone or in Combination, on Achieving Disease Recovery by Day 5. — 22; 24; 20; 18…
Phase 2 N=58 An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.
Atopic Dermatitis
Primary: Change in EASI Score From Baseline to Week 16 — -15.3; -3.5 score on a scale — p=0.003
Phase 2 N=209 Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older
Influenza
Primary: Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Response for Each Homologous Influenza Strain on Day 0 — 87.5704; 71.2385; 69.1840; 60.7941…
Phase 2 N=129 Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction
Posterior Blepharitis · Meibomian Gland Dysfunction
Primary: Adverse Events — 1; 1; 2; 0 adverse events